MEI Pharma Inc. (NASDAQ:MEIP) has a beta value of 1.53 and has seen 0.42 million shares traded in the last trading session. The company, currently valued at $326.51M, closed the last trade at $2.89 per share which meant it lost -$0.01 on the day or -0.34% during that session. The MEIP stock price is -58.13% off its 52-week high price of $4.57 and 20.76% above the 52-week low of $2.29. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.28 million shares traded. The 3-month trading volume is 438.89K shares.
The consensus among analysts is that MEI Pharma Inc. (MEIP) is a Buy stock at the moment, with a recommendation rating of 1.80. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 9 have rated it as a Hold, with 9 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.17.
MEI Pharma Inc. (NASDAQ:MEIP) trade information
Sporting -0.34% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/03/21 when the MEIP stock price touched $2.89 or saw a rise of 1.7%. Year-to-date, MEI Pharma Inc. shares have moved 9.47%, while the 5-day performance has seen it change 4.71%. Over the past 30 days, the shares of MEI Pharma Inc. (NASDAQ:MEIP) have changed 8.65%. Short interest in the company has seen 11.42 million shares shorted with days to cover at 24.47.
Wall Street analysts have a consensus price target for the stock at $10.17, which means that the shares’ value could jump 71.58% from current levels. The projected low price target is $7.00 while the price target rests at a high of $13.00. In that case, then, we find that the current price level is -349.83% off the targeted high while a plunge would see the stock gain -142.21% from current levels.
MEI Pharma Inc. (MEIP) estimates and forecasts
Figures show that MEI Pharma Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -20.17% over the past 6 months, with this year growth rate of 44.05%, compared to 18.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 10.50% and -300.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be -32.20%.
7 analysts offering their estimates for the company have set an average revenue estimate of $3.57 million for the current quarter. 2 have an estimated revenue figure of $24 million for the next quarter concluding in Sep 2021. Year-ago sales stood $25.5 million and $4.28 million respectively for this quarter and the next, and analysts expect sales will shrink by -86.00% for the current quarter and 460.70% for the next.
Earnings growth for 2021 is a modest -11.80% while over the next 5 years, the company’s earnings are expected to decrease by -0.10%.
MEI Pharma Inc. is expected to release its next earnings report on February 04 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
MEI Pharma Inc. (NASDAQ:MEIP)’s Major holders
Insiders own 2.84% of the company shares, while shares held by institutions stand at 74.16% with a share float percentage of 76.33%. Investors are also buoyed by the number of investors in a company, with MEI Pharma Inc. having a total of 147 institutions that hold shares in the company. The top two institutional holders are MPM ONCOLOGY IMPACT MANAGEMENT LP with over 10.14 million shares worth more than $34.77 million. As of Mar 30, 2021, MPM ONCOLOGY IMPACT MANAGEMENT LP held 9.00% of shares outstanding.
The other major institutional holder is NEA Management Company, LLC, with the holding of over 8.53 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $29.27 million and represent 7.58% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund. As of Mar 30, 2021, the former fund manager holds about 3.72% shares in the company for having 4.19 million shares of worth $14.38 million while later fund manager owns 3.32 million shares of worth $11.39 million as of Mar 30, 2021, which makes it owner of about 2.95% of company’s outstanding stock.